Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Deciphera Pharmaceuticals stock | 66.18

Own Deciphera Pharmaceuticals stock in just a few minutes.


Fact checked

Deciphera Pharmaceuticals, Inc is a biotechnology business based in the US. Deciphera Pharmaceuticals shares (DCPH) are listed on the NASDAQ and all prices are listed in US Dollars. Deciphera Pharmaceuticals employs 255 staff and has a trailing 12-month revenue of around USD$7.2 million.

How to buy shares in Deciphera Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Deciphera Pharmaceuticals. Find the stock by name or ticker symbol: DCPH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Deciphera Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$66.18, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Deciphera Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Deciphera Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Deciphera Pharmaceuticals share price

Use our graph to track the performance of DCPH stocks over time.

Deciphera Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$66.18
52-week range USD$33.1 - USD$71.11
50-day moving average USD$51.3969
200-day moving average USD$51.8512
Wall St. target price USD$73
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.312

Buy Deciphera Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Deciphera Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Deciphera Pharmaceuticals price performance over time

Historical closes compared with the close of $66.18 from 2020-11-16

1 week (2020-11-23) 7.31%
1 month (2020-10-30) 13.97%
3 months (2020-08-28) 47.92%
6 months (2020-05-29) 12.99%
1 year (2019-11-29) 39.95%
2 years (2018-11-30) 153.86%
3 years (2017-11-30) 233.23%
5 years (2015-11-27) N/A

Deciphera Pharmaceuticals financials

Revenue TTM USD$7.2 million
Gross profit TTM USD$25 million
Return on assets TTM -36.05%
Return on equity TTM -62.54%
Profit margin 0%
Book value $11.05
Market capitalisation USD$3.3 billion

TTM: trailing 12 months

Shorting Deciphera Pharmaceuticals shares

There are currently 4.2 million Deciphera Pharmaceuticals shares held short by investors – that's known as Deciphera Pharmaceuticals's "short interest". This figure is 10.6% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting Deciphera Pharmaceuticals shares can be evaluated.

Deciphera Pharmaceuticals's "short interest ratio" (SIR)

Deciphera Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Deciphera Pharmaceuticals shares currently shorted divided by the average quantity of Deciphera Pharmaceuticals shares traded daily (recently around 411862.20472441). Deciphera Pharmaceuticals's SIR currently stands at 10.16. In other words for every 100,000 Deciphera Pharmaceuticals shares traded daily on the market, roughly 10160 shares are currently held short.

However Deciphera Pharmaceuticals's short interest can also be evaluated against the total number of Deciphera Pharmaceuticals shares, or, against the total number of tradable Deciphera Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Deciphera Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Deciphera Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.1055% of the tradable shares (for every 100,000 tradable Deciphera Pharmaceuticals shares, roughly 106 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Deciphera Pharmaceuticals.

Find out more about how you can short Deciphera Pharmaceuticals stock.

Deciphera Pharmaceuticals share dividends

We're not expecting Deciphera Pharmaceuticals to pay a dividend over the next 12 months.

Deciphera Pharmaceuticals share price volatility

Over the last 12 months, Deciphera Pharmaceuticals's shares have ranged in value from as little as $33.1 up to $71.11. A popular way to gauge a stock's volatility is its "beta".

DCPH.US volatility(beta: 1.73)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Deciphera Pharmaceuticals's is 1.7314. This would suggest that Deciphera Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Deciphera Pharmaceuticals overview

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site